Quotient Acquires Charles River’s CDMO Unit
Quotient Clinical, a Nottingham, UK-based early phase drug development services provider, has acquired QS Pharma, Charles River Laboratories International’s contract development and manufacturing organization unit based near Philadelphia.
Founded in 2002, QS Pharma specializes in the formulation development and manufacturing of small molecule drug products and supports customer programs from the development stage through to commercialization. Quotient gains QS Pharma’s capability in potency molecule manufacturing.
This acquisition expands Quotient’s footprint in the US following its recent acquisition of SeaView Research, a Miami, Florida-based clinical research organization, this month. The two acquisitions boost Quotient’s capability to replicate its proprietary Translational Pharmaceutics technology platform in the US, which integrates clinical testing with formulation development and real-time GMP manufacturing.
Source: Quotient Clinical